BNIP1: A Potential Drug Target and Biomarker (G662)

Target Name: BNIP1

NCBI ID: G662

BNIP1

BNIP1: A Potential Drug Target and Biomarker

BNIP1 (BCL2/adenovirus E1B 19 kDa protein-interacting protein 1) is a protein that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and function make it an attractive target for researchers to study and develop new treatments.

BNIP1 is a 19 kDa protein that is expressed in various tissues and cells in the body. It is highly conserved and has a single known function, which is to interact with the protein BCL2 (Bcl-2). BCL2 is a well-known protein that has been implicated in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

The interaction between BNIP1 and BCL2 suggests that BNIP1 may be a negative regulator of BCL2's activity. This means that when BNIP1 is present in a cell, it may be preventing BCL2 from doing its job, leading to a potential therapeutic target.

One of the key challenges in studying BNIP1 is its expression and function, as there is limited information available on the subject. However, research has shown that BNIP1 is highly expressed in various tissues and cells, including brain, spleen, and pancreas. It is also known to be involved in various signaling pathways, including the TGF-β pathway, which is involved in cell growth and differentiation.

In addition to its potential drug target properties, BNIP1 has also been identified as a potential biomarker for various diseases. Its expression has been shown to be elevated in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This suggests that BNIP1 may be a useful biomarker for these diseases and could be used in clinical trials to monitor disease progression and response to therapeutic treatments.

The identification of BNIP1 as a potential drug target and biomarker has significant implications for the development of new treatments for various diseases. By targeting BNIP1 with small molecules or other therapeutic agents, researchers may be able to improve treatment outcomes for these diseases.

More research is needed to fully understand the function and potential of BNIP1. By studying its structure and function, researchers may be able to identify new therapeutic targets and develop new treatments for various diseases. As BNIP1 continues to be studied, it is clear that it has the potential to be a valuable tool in the fight against disease.

Protein Name: BCL2 Interacting Protein 1

Functions: As part of a SNARE complex may be involved in endoplasmic reticulum membranes fusion and be required for the maintenance of endoplasmic reticulum organization (PubMed:15272311). Also plays a role in apoptosis (PubMed:7954800, PubMed:15272311, PubMed:23896122). It is for instance required for endoplasmic reticulum stress-induced apoptosis (PubMed:23896122). As a substrate of RNF185 interacting with SQSTM1, might also be involved in mitochondrial autophagy (Probable)

The "BNIP1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about BNIP1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets